Business Wire

Diligent Launches AI Act Toolkits to Support Organizations in Complying with New EU AI Regulation

18.9.2024 10:00:00 CEST | Business Wire | Press release

Share

Toolkits enable customers to identify AI systems, classify associated risk, ensure compliance with the EU's AI Act obligations and uphold global ethical best practices.

Diligent, a leading GRC SaaS company, today announced the launch of its new Artificial Intelligence (AI) Act Toolkits, designed to help corporate secretaries, legal and compliance teams, chief technology officers, chief information security officers and audit teams navigate the increasing complexity of AI governance and AI regulatory compliance. The Toolkits empower businesses operating inside and outside the European Union (EU) to understand and comply with the requirements of the EU's AI Act, and to integrate a responsible and ethical approach to AI adoption that builds trust in new technologies and adheres to global standards for AI governance.

“As the AI landscape evolves, organizations are challenged to balance innovation with regulatory compliance and ethical considerations,” said Keith Fenner, Senior Vice President & General Manager, International at Diligent. “The EU's AI Act represents a significant regulatory milestone to ensure AI systems are safe, transparent, and respect fundamental rights. We’re thrilled to offer a solution that helps customers identify and map regulatory obligations, implement best practice controls, and govern AI responsibly. This ensures compliance with evolving global regulations while accelerating the adoption of AI technology and delivering value.”

There are three toolkits available within the Diligent One Platform:

  • AI Discovery and Risk Classification Toolkit – This toolkit helps customers identify their AI systems and perform the required risk classification exercise. It also provides access to an extensive library of AI literacy and best practice governance resources for the board, senior management and employees to accelerate organizational readiness and elevate AI governance. The toolkit is available to all Diligent One Platform customers.
  • AI Act IT Compliance Toolkit – This toolkit helps organizations understand regulatory requirements, map them against suggested controls, and document compliance. It offers suggested control mapping to the AI Act’s regulatory requirements, gap identification, a dashboard summary for control assessment, a remediation summary and notifications to key stakeholders.
  • AI Act Risk Management Toolkit – This comprehensive risk management toolkit supports a complete AI governance program. It features a risk heatmap for reviewing and prioritizing risks, a dashboard summarizing AI systems by risk level, a pre-configured AI threat library, and tools for continuous monitoring to ensure policy adherence and compliance.

In a world where, according to surveys, 78% of employees bring their own AI tools to work and 86% of businesses use some form of AI without the board’s awareness, Diligent's AI Act Toolkits are designed to support compliance, governance and risk management efforts. The Toolkits help customers to identify their AI systems and models, apply a risk-based classification, understand their obligations as providers and deployers under the AI Act, build an AI governance framework and monitor ongoing compliance. This helps to ensure that AI systems are implemented responsibly and ethically, and in a manner that documents compliance efforts in accordance with customer, partner, employee and regulator expectations.

Diligent’s Toolkits provide a robust framework for assessing and managing the risks associated with AI systems, helping organizations incorporate ethical considerations into their AI development, and supporting ongoing compliance with the EU’s AI Act. As AI becomes increasingly integral to business strategy, the Toolkits reflect Diligent's dedication to supporting ethical AI practices and helping its customers stay ahead of regulatory changes.

To learn more about the AI Act Toolkits from Diligent, visit: https://www.diligent.com/lp/eu-ai-act-compliance

About Diligent

Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.

Follow Diligent on LinkedIn, X (Twitter) and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918400561/en/

Contacts

Media

Media
Julia Stoyanov
Communications Director, Diligent  
+1 (604) 669-4225
Jhanbury@diligent.com

Jhanbury@diligent.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye